Vitamin D in the prevention and treatment of type-2 diabetes and associated diseases: a critical view during COVID-19 time

• Published in: Minerva Biotechnology and Biomolecular Research Vol. 33; no. 2; p. 65
• Main Authors: FALALYEYEVA, Tetyana, KOMISARENKO, Iuliia, YANCHYSHYN, Andrii, KOVALCHUK, Oleksandr, LOZKO, Yuliia, TSYRYUK, Olena, FAGOONEE, Sharmila, KOBYLIAK, Nazarii
• Format: Journal Article
• Language: English
• Published: Torino Edizioni Minerva Medica 01.06.2021
• Subjects: Convalescence; COVID-19; Diabetes; Diabetes mellitus; Fatty liver; Inflammation; Insulin; Metabolic disorders; Pandemics; Steatosis; Structure-function relationships; Vitamin D; Vitamin D3; Vitamin deficiency
• ISSN: 2724-542X; 1120-4826; 2724-5934; 1827-160X
• DOI: 10.23736/S2724-542X.21.02766-X

Vitamin D deficiency has been recognized as a pandemic with many negative health consequences in many countries. Today the mechanisms of anti-inflammatory and hepatoprotective action of vitamin D3 (cholecalciferol) and in general the scientific justification for its effective use in the clinic of type-2 diabetes (T2D) is actively studied in the scientific literature. We performed a review evaluating, that the treatment with vitamin D3 may increase the chances for successful convalescence: reduction of inflammation and hepatic steatosis; an increase of glycemic control and insulin sensitivity. The above-mentioned issue necessitates a deep and comprehensive study of an important scientific problem, which is the need for clinical justification of the effectiveness of vitamin D3 for the prevention and correction of metabolic disorders and structural and functional changes in the liver in T2D.